In the last 2 decades, clinical genetics on hereditary colorectal syndromes has shifted from just a molecular characterization of the different syndromes to the estimation of the individual risk of cancer and appropriate risk reduction strategies. In the last years, new specific therapies for some subgroups of patients have emerged as very effective alternatives. At the same time, germline multigene panel testing by next-generation sequencing (NGS) technology has become the new gold standard for molecular genetics.
Introduction
Identification of individuals and families with clinical criteria for early referral to a specialized genetic counseling unit (GCU) has been the basis for preventive medicine in familial-hereditary susceptibility to colorectal cancer so far. Genetic counseling and risk reduction strategies have avoided many new cancer diagnoses and have helped these individuals understand and adapt to all the implications of genetic predisposition to colorectal cancer.
In the near future, somatic and germline multigene panel testing will be incorporated into the routine care of cancer, early from its diagnosis. Targeted therapies candidates will be identified through these predictive molecular profiles and 1 3 at the same time all known and actionable hereditary colorectal cancer syndromes will be screened as well.
The main hereditary colorectal cancer syndromes will be reviewed in this guideline with their main clinical, molecular features and their appropriate surveillance recommendations.
Materials and methods
A medical literature review was conducted in NCBI Pub-Med/EMBASE databases on the topics of the guideline. Evidence level and strength of the recommendations were based on GRADE http://www.grade worki nggro up.org/ [1] [2] [3] ( Table 1 ).
Lynch syndrome (OMIM 120435)
Lynch syndrome (LS) is an autosomal dominant inherited cancer predisposition disease. Its estimated general population prevalence is 1 in 279 [4] . LS accounts for about 3% of colorectal cancer (CRC) [5] and 2% of endometrial cancer (EC) cases [6] . CRC is the most common associated tumor, usually right-sided, poorly differentiated, with mucinous features or medullary growth pattern, abundant infiltrating lymphocytes, propensity for synchronous and/ or metachronic tumors [7] , and a better prognosis in the non-metastatic setting [8, 9] . LS also predisposes to EC, small intestinal, urinary tract, pancreaticobiliary, gastric and ovarian tumors, and slightly to breast and prostate cancers [7, [10] [11] [12] . Muir-Torre syndrome is characterized by skin tumors (sebaceous neoplasms, keratoacanthomas) and Turcot's syndrome includes glial brain tumors [7, 10] . The age of onset is younger compared with sporadic counterparts: 45-60 years old (years) for CRC and 50 years for EC [13] .
Lynch syndrome is caused by pathogenic germline variants in the DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6, or PMS2 (and in the non-MMR gene EpCAM, in which deletions induce epigenetic silencing of MSH2) [10, 14] . When a second "hit" of somatic mutation occurs, the MMR function fails leading to cancers with microsatellite instability (MSI) and hypermutation phenotype. Deficient MMR (dMMR) and MSI are not exclusive to the LS and are also likely in sporadic cancers caused by MLH1 promoter hypermethylation [15] or double somatic MMR mutations [16] .
The age-specific cumulative risk could depend on genotype and sex [12, 13, [17] [18] [19] (Table 2) . MSH2 mutation carriers have a higher risk of extracolonic cancers [12] . EpCAM deletions close to the MSH2 promoter are associated with increased risk of EC [20] . MSH6 and PMS2 mutations have a lower penetrance [4] , except for EC in MSH6 carriers, who also present with cancer at later ages [19, 21] .
LS diagnosis
Universal strategy with molecular analyses in unselected CRC or EC adds diagnostic sensitivity for LS over clinical criteria, with a favorable cost-effectiveness profile [22] [23] [24] [25] . This information has prognostic and therapeutic value for Table 1 Evidence levels and strength of recommendation
Evidence levels
A: High. Randomized well-designed clinical trials/well-conducted meta-analysis. It is unlikely that future studies on the topic will modify confidence in the outcome B: Moderate. Non-randomized prospective studies. It is likely that future studies on the topic will modify the confidence in the estimated outcome C: Low or very low. Observational studies. Future studies on the topic will very likely change not only the confidence in the outcome but the outcome itself Strength of recommendation 1. Strong recommendation on the measure/intervention we are considering: advantages of the intervention outweigh the risks and also are cost-efficient 2. Weak recommendation: advantages and disadvantages are not far from each other , p = 0.04) [26] . In a prospective study of > 15.000 unselected cancer patients with 50 different histologies, a similar NGS device increased LS diagnostic sensitivity over revised Bethesda Criteria (rBC) plus universal strategy [27] . Somatic NGS panels are available in clinical practice for precision oncology due to their predictive value. Direct germline multigene NGS in unselected patients with CRC increases diagnostic sensitivity for less prevalent hereditary syndromes more than for LS [5, 28] (Fig. 1 ). When there are no tumor samples, fulfillment of rBC or a ≥ 2.5% likelihood of LS on the validated PREMM 5 prediction model [29] can be used for referral to a GCU. Although NGS is continuously less expensive, cost-effectiveness studies for LS diagnostic strategies that incorporate these platforms are lacking. Recommendation Different screening strategies for LS of all newly diagnosed CRC and EC can be considered including tumor tests for defective MMR function and/or highlevel MSI and/or NGS tumor sequencing including BRAF.
In case of lack of expression of MLH1 and PMS2 by immunohistochemistry, BRAFV600E mutation and/or MLH1 promoter hypermethylation should be carried out to rule out sporadic cases.
Patients with molecular profiles compatible with LS should be referred to GCU for appropriate counseling and NGS germline genetic testing.
In families with fulfillment of rBC or a ≥ 2.5% likelihood of LS on the PREMM 5 prediction model, prevalent and/or previous CRC and/or EC should follow the same screening procedure before considering referral to GCU (evidence level B, strength 1). 
Diagnosis of Endometrial

Management of LS: cancer prevention
Screening and surgical management for CRC prevention
Prospective data with long-term follow-up demonstrate that early colonoscopy repeated frequently in LS carriers significantly reduces CRC incidence, CRC associated mortality, and overall mortality [30] . Recommendation Colonoscopies should be performed every 1-2 years for healthy individuals with LS, beginning at 20-25 years or 2-5 years before the youngest age at which CRC was diagnosed in the family if this occurred before 25 years (evidence level B, strength 1).
Risk of metachronous CRC is up to 62% at 30-year follow-up among patients with LS and segmental resection of the primary tumor [31] . In a meta-analysis of 6 studies (mean 9-year follow-up), rates of metachronous CRC were reduced by 3.4 times with subtotal colectomy, although a survival benefit was not found [32] .
Recommendation Extended colonic resection may be an option for young patients with CRC, severe LS phenotype, good bowel function, no comorbidities, and compliance with endoscopic surveillance after surgery (evidence level A, strength 1).
Risk-reducing surgery for EC and ovarian cancer (OC)
Observational data have shown that hysterectomy and salpingo-oophorectomy have efficacy for prevention of EC and OC in women with LS, although it remains unclear whether surgery confers any survival benefit [33] . Psychological, cardiovascular, endocrinologic, skeletal, and sexual consequences of early onset menopause, and the risk burden associated with specific genes must be kept in mind to discuss the optimal timing of risk-reducing surgery.
Recommendation Risk-reducing hysterectomy and salpingo-oophorectomy at the completion of childbearing and/ or since the early 40s (evidence level C, strength 1) should be considered.
Chemotherapeutic prevention
A long-term analysis in CAPP2 study demonstrated a marked reduction in CRC incidence (incidence rate ratio [IRR], 0.37 [95% CI 0.18-0.78], p = 0.008) and in any LSassociated cancer (IRR, 0.42 [95% CI 0.25-0.72], p = 0.001) among LS carriers who took aspirin at dose of 600 mg/day for 2 or more years compared with those randomly assigned to placebo [34] .
Recommendation Daily aspirin can be considered for LS cancer prevention, although the ideal dose and duration of use are as yet undefined (evidence level A, strength 2).
Management of LS: specific issues on cancer treatment
Adjuvant chemotherapy with 5-fluorouracil did not result in a survival benefit in subgroup analyses of patients with stage II colon cancer with dMMR [35] .
In patients with dMMR metastatic CRC and previous cytotoxic agents failure, anti-programmed death 1 (PD-1) antibody nivolumab resulted in objective response rate (ORR) of 31.1% (95% CI 20.8-42.9) (median follow-up time, 12.0 months) [36] . In the same setting, the combination of nivolumab plus ipilimumab (anti-cytotoxic T-lymphocyte antigen 4 antibody) reached an ORR of 55% (95% CI 45.2-63.8) (median follow-up time, 13.4 months), with progression-free survival and overall survival rates at 12 months of 71% and 85%, respectively, and a manageable treatment-related grade 3-4 toxicity in 32% of patients [37] . In dMMR cancers across 12 different histologies, ORR of 53% (95% CI 42-64) and complete responses in 21% of patients (median follow-up time, 12.5 months) were observed with anti-PD-1 antibody pembrolizumab [38] .
Recommendation Adjuvant chemotherapy is not indicated in stage II LS-associated colon cancer (evidence level B, strength 1). Different immunotherapy options are valid for pretreated recurrent or metastatic LS-associated cancers (evidence level B, strength 1).
Familial adenomatous polyposis
Familial adenomatous polyposis (FAP) was first associated with mutations in the APC, and later in the MUTYH. Additional genes such as POLE, POLD1, NTHL1, MSH3, GREM1 have been recently associated. Extracolonic manifestations may be present and help with the clinical diagnosis (Table 3 ).
APC-associated polyposis, FAP or AAP (OMIM 175100) [39, 40]
It is an autosomal dominant inherited disease caused by germline mutations (> 85% point mutations, 10-15% large rearrangements) in APC which encodes a protein with a significant role in the Wnt-β-catenin signaling. Up to 30% of carriers are due to de novo mutations or to somatic mosaicism. There are genotype-phenotype correlations. The clinical presentations are: (a) classic FAP, ≥ 100 polyps, appearing between 10 and 30 years, first located in rectum and sigma afterwards along the colon and development of CRC in almost 100% if untreated, at a mean age of 39 years. (b) Attenuated FAP (AFAP), < 100 polyps located in proximal colon and lesser risk of CRC, 70%, at a mean age of 50-55 years. (c) Gastric adenocarcinoma and proximal polyposis of the stomach (GAPP), none or few polyps in colon. 
MUTYH-associated polyposis, MAP (OMIM 608456) [39, 41]
It is an autosomal recessive disease caused by bi-allelic, homozygous or compound heterozygous, germline mutations (> 99% point mutations, < 1% large rearrangement) in MUTYH which encodes a glycosylase of DNA base excision repair system. Somatic G:C to T:A transversions result in genes implicated in CRC carcinogenesis, such as APC or KRAS. The most frequent phenotype is AFAP, at a mean age of 45 years, but maybe classic FAP, serrated polyposis and few individuals develop CRC without polyposis. Genotype-phenotype correlation has been described. The risk of CRC is 43-100% at the age of 50 years. For the study of FAP, single gene testing has been the traditional approach, but the use of a multigene panel should be specially considered in attenuated FAP.
Recommendation Criteria for referral to a GCU and APC/MUTYH or multigene panel testing (evidence level B, strength 1): 
Colorectal surveillance
In classical FAP, flexible sigmoidoscopy or colonoscopy should be carried out every 1-2 years, starting at age 12-15 years. If adenomas are found at sigmoidoscopy, then it should be annual colonoscopy [43] . In AFAP, colonoscopy should be performed every 1-2 years starting at age 18-20 years and surgery is indicated if there is a high number of adenomas. In MAP, colonoscopy should be performed every 1-2 years, starting at 18-20 years and if polyps cannot be controlled endoscopically, colectomy should be considered [43, 44] . For MUTYH heterozygote, colonoscopy should be performed every 5 years, beginning at age 40 years or 10 years prior to age of first-degree relative's age at CRC diagnosis [42, 44] .
Recommendation Surgery is indicated if there is a high number of adenomas or a high degree of dysplasia (evidence level B, strength 1).
Surgical options of colon and rectum
Surgical options in FAP patients are total abdominal colectomy with ileorectal anastomosis (TAC/IRA) or total proctocolectomy with pouch anal anastomosis (TPC/IPAA) [42] [43] [44] . Surveillance of rectum depends on the type of surgery [42, 43] .
Recommendation TPC/IPAA or TAC/IRA should be carried out depending on age, severity of rectal polyposis and risk of developing desmoids. In FAP, it is usually recommended in the 2nd decade of life (evidence level B, strength 1). IPAA is generally recommended for FAP, and IRA for AFAP and MAP. Afterwards, surveillance of the rectum should be carried out every 6-12 months if rectal tissue remains, and every 1-3 years if ileoanal pouch is present, depending on polyp burden (evidence level B, strength 1). [42, 44] . Duodenal adenomas are managed by endoscopic polypectomy, although duodenectomy or duodenal pancreatectomy may be necessary in advanced cases [43] .
Extracolonic manifestations
Patients with classical FAP have a lifetime thyroid cancer risk of 2-6% and annual surveillance is recommended [42, 44] .
Treatments for desmoid tumors are surgery, non-steroid anti-inflammatory drugs (NSAIDs), anti-oestrogen agents, chemotherapy, imatinib, sorafenib, pazopanib and radiotherapy [44] .
The absolute risk for hepatoblastoma in FAP is estimated at less than 2% and it occurs prior to the age of 3 years [42] .
Recommendation Surveillance of duodenal adenomas is based on the Spigelman's stage (evidence level B, strength 1). In MAP, upper endoscopy is recommended at 
Chemoprevention
The use of NSAIDs (sulindac or celecoxib) has been shown to reduce the number and extent of CRC and duodenal adenomas, but without the clinical benefit of decrease in cancer risk [42, 43] . Due to the cardiovascular risk of NSAIDs, no drug has been approved.
Recommendation The use of NSAIDs to prevent CRC and duodenal adenomas needs to be balanced with the side effects (evidence level A, strength 2).
Hamartomatous polyposis and other non-adenomatous polyposis
There are several classifications for hereditary syndromes with polyposis; one of the most accepted distributes them into four large groups: adenomatous, hamartomatous, serrated and mixed polyposis [45] .
These PS are very rare with the exception of serrated polyposis syndrome (SPS); the estimated incidence for PTEN hamartoma tumor syndrome is 1 in 200,000-250,000; for Peutz-Jeghers syndrome it is 1 in 250,000; for juvenile polyposis syndrome it is from 1 to 1.6 in 100,000. The SPS prevalence is higher than for other PS, including FAP; overall, its seems lower than 0.09-42 in 10,000 in colonoscopy-based CRC screening programs, but it is considerably higher in positive fecal occult blood test populations, with estimates of 0.34-0.66% or 31-80 in 10,000 [46] [47] [48] [49] [50] [51] . Sessile serrated polyposis cancer syndrome (SSPCS) is a very rare disorder caused by heterozygous mutation in the RNF43 gene [49] . While most SPS cases are sporadic, evidence suggests that this syndrome exhibits a genetic component at least occasionally. The higher prevalence of CRC and serrated polyps in first-degree relatives (FDRs) as compared to the general population supports this theory. Table 3 summarizes the main characteristics and recommendations of surveillance of Adenomatous polyposis, Hamartomatous polyposis and Non-adenomatous PS according to recommendations of the European Society of Gastrointestinal Endoscopy (ESGE) Guideline [46] or, in the rest of the cases, suggested by other referenced authors.
Multigene panel testing in familial CRC
The introduction of NGS technologies for the genetic diagnosis of hereditary cancer predisposition syndromes represents a surpassing progress in the knowledge of this field. Multigene panel testing allows the simultaneous analysis Table 5 List of genes associated to CRC and polyposis with their classification attending to their strength of evidence and the risk level
In bold letter, genes with concordant classification among the three sources of information (with strong higher-ranking evidences). Underlined letter, genes with discordant classification, with at least one of the sources considering not well established, moderate or limited Gene Disease entity (inheritance)
Strength of evidence/classification
Risk level [53] ClinGen [54] NCCN [53] Lorans et al. [ of multiple genes by NGS increasing the diagnostic yield, reducing the response times in a cost-effective manner, when compared to iterative single gene or phenotype-driven testing [52] . On the other hand, there is a higher chance of identifying variants of uncertain significance that are not actionable, or variants for which clinical management is uncertain such as finding a pathogenic variant in a moderate risk gene [53] .
There is a high variability in the genes included across the multigene panels for CRC. Although a batch of genes considered clinically actionable with quantified magnitude of risk are present in virtually all panels, there is a significant amount of genes that lack comprehensive validation or have less evidence of association with CRC/polyposis and consequently minimal clinical utility, that are included in many multigene panels. In fact, recent data from the ClinGen Clinical Validity framework show that < 60% of the genes on clinically available panels have strong or definitive evidence of association with hereditary colorectal cancer or polyposis, and > 40% have only moderate, limited, disputed, or refuted evidence [54] .
The current lack of consensus regarding inclusion of genes in CRC panels represents a challenge in patient counseling and management (Table 4 ). There is an urgent need to provide consensus on the genes included in multigene panels. This consensus should be based on structured assessment of the clinical relevance of the genes, with standardized reporting and clinical management guidelines [55] .
For the current guidelines, we have reviewed the available information from reputable sources with expert panels to define strength of evidence and evaluate the clinical utility of genes associated with CRC and polyposis. Therefore, we considered the following sources: (i) the NCCN Guidelines for colorectal cancer v1.2019 [53] , (ii) ClinGen Clinical Validity framework [54] and (iii) Lorans et al.'s review [55] . The applied criteria to evaluate the level of validation are slightly different among them with some discordant results. In Table 5 , the list of genes considered to have strong higherranking evidences for their association to hereditary forms of CRC/polyposis in at least one of the considered sources is shown. The total number of included genes is 18. Eleven genes have fully concordant classification among the three sources: APC, BMPR1A, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, SMAD4 and STK11, while seven genes show discordant classification: AXIN2, BLM, GREM1, NTHL1, POLD1, POLE and TP53. Multigene panel testing for hereditary CRC and polyposis is a rapidly evolving landscape. A periodical review and consequent actualization of panels, if necessary, is recommended.
Recommendation Multigene panel testing for hereditary CRC and polyposis should include the genes: -APC, BMPR1A, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, SMAD4 and STK11 (evidence level A, strength 1). -AXIN2, BLM, GREM1, NTHL1, POLD1, POLE and TP53 (evidence level B, strength 2).
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